Protein kinase inhibitors offer a potential treatment to address pivotal molecular mechanisms of AD.[63] GSK‐3β is highly activated in individuals diagnosed with mild cognitive impairment and AD.[64] Different research groups provide substantial evidence regarding the role of GSK‐3β in the implications of AD, including its correlation with the hyperphosphorylation of tau, increased production of Aβ, cognitive deficits, neuroinflammation, and neuronal damage loss.[65]. The gene discussed is MAPT; the disease is Cognitive impairment.